(Q46727401)

24 December 2017

title

Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering? (English)

1 reference

24 December 2017

1 reference

Theodosios D. Filippatos

3

1 reference

24 December 2017

author name string

Haralampos J Milionis

1

1 reference

24 December 2017

Irene F Gazi

2

1 reference

24 December 2017

Vasilios Tzovaras

4

1 reference

24 December 2017

George Chasiotis

5

1 reference

24 December 2017

John Goudevenos

6

1 reference

24 December 2017

Konstantine Seferiadis

7

1 reference

24 December 2017

Moses S Elisaf

8

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

published in

Angiology

1 reference

24 December 2017

volume

56

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

585-592

1 reference

24 December 2017

Rosuvastatin: a review of its use in the management of dyslipidemia

cites work

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Correct homeostasis model assessment (HOMA) evaluation uses the computer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Statins and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Early vascular benefits of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Release of platelet constituents by monosodium urate crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Homocysteine and cardiovascular disease: current evidence and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Homocysteine-lowering treatment: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970505600510

10.1177/000331970505600510

21 January 2018

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017